2,5-Dimethoxy-4-methylphenylcyclopropylamine
2,5-Dimethoxy-4-methylphenylcyclopropylamine (DMCPA) is a lesser-known psychedelic drug and a substituted amphetamine. DMCPA was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage range is listed as 15–20 mg and the duration is listed as 4–8 hours.[1] DMCPA produces open-eye visuals, anorexia, and psychedelic dreams. Shulgin gives it a +++ on the Shulgin Rating Scale.
Names | |
---|---|
IUPAC name
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropanamine | |
Identifiers | |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider | |
PubChem CID |
|
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C12H17NO2 | |
Molar mass | 207.273 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Legality
United Kingdom
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]
Pharmacology
Very little data exists about the pharmacological properties, metabolism, and toxicity of DMCPA.
References
- DMCPA Entry in PiHKAL
- "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.